KROMATID delivers next-generation genomic structural analysis solutions for gene and cell therapy developers, enabling precise detection of chromosomal structural rearrangements with unmatched clarity and resolution. By combining proprietary imaging and bioinformatics capabilities, KROMATID supports therapeutic innovation from discovery through regulatory approval.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/22/25 | $8,000,000 | Series C |
BroadOak Capital Partners | undisclosed |
